165 related articles for article (PubMed ID: 36037109)
1. β-Eudesmol Inhibits the Migration of Cholangiocarcinoma Cells by Suppressing Epithelial-Mesenchymal Transition via PI3K/AKT and p38MAPK Modulation.
Acharya B; Chajaroenkul W; Na-Bangchang K
Asian Pac J Cancer Prev; 2022 Aug; 23(8):2573-2581. PubMed ID: 36037109
[TBL] [Abstract][Full Text] [Related]
2. Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways.
Acharya B; Chaijaroenkul W; Na-Bangchang K
J Pharm Pharmacol; 2021 Aug; 73(9):1191-1200. PubMed ID: 33885818
[TBL] [Abstract][Full Text] [Related]
3. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
5. Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
Liu LZ; He YZ; Dong PP; Ma LJ; Wang ZC; Liu XY; Duan M; Yang LX; Shi JY; Zhou J; Fan J; Gao Q; Wang XY
Oncotarget; 2016 Nov; 7(46):75210-75220. PubMed ID: 27655691
[TBL] [Abstract][Full Text] [Related]
6. Tetraspanin 1 promotes epithelial-to-mesenchymal transition and metastasis of cholangiocarcinoma via PI3K/AKT signaling.
Wang Y; Liang Y; Yang G; Lan Y; Han J; Wang J; Yin D; Song R; Zheng T; Zhang S; Pan S; Liu X; Zhu M; Liu Y; Cui Y; Meng F; Zhang B; Liang S; Guo H; Liu Y; Hassan MK; Liu L
J Exp Clin Cancer Res; 2018 Dec; 37(1):300. PubMed ID: 30514341
[TBL] [Abstract][Full Text] [Related]
7. Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.
Srijiwangsa P; Ponnikorn S; Na-Bangchang K
BMC Pharmacol Toxicol; 2018 Jun; 19(1):32. PubMed ID: 29914576
[TBL] [Abstract][Full Text] [Related]
8. Brusatol suppresses the growth of intrahepatic cholangiocarcinoma by PI3K/Akt pathway.
Chen Z; He B; Zhao J; Li J; Zhu Y; Li L; Bao W; Zheng J; Yu H; Chen G
Phytomedicine; 2022 Sep; 104():154323. PubMed ID: 35858516
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/β-catenin signaling and inhibits apoptosis in cholangiocarcinoma.
Xue W; Dong B; Zhao Y; Wang Y; Yang C; Xie Y; Niu Z; Zhu C
Cell Oncol (Dordr); 2021 Dec; 44(6):1351-1361. PubMed ID: 34796468
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-α (TNF-α) stimulates the epithelial-mesenchymal transition regulator Snail in cholangiocarcinoma.
Techasen A; Namwat N; Loilome W; Bungkanjana P; Khuntikeo N; Puapairoj A; Jearanaikoon P; Saya H; Yongvanit P
Med Oncol; 2012 Dec; 29(5):3083-91. PubMed ID: 22903530
[TBL] [Abstract][Full Text] [Related]
11. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
12. ARHGAP21 Is Involved in the Carcinogenic Mechanism of Cholangiocarcinoma: A Study Based on Bioinformatic Analyses and Experimental Validation.
Wang Z; Wu S; Wang G; Yang Z; Zhang Y; Zhu C; Qin X
Medicina (Kaunas); 2023 Jan; 59(1):. PubMed ID: 36676763
[No Abstract] [Full Text] [Related]
13. IL-8 is a novel prometastatic chemokine in intrahepatic cholangiocarcinoma that induces CXCR2-PI3K/AKT signaling upon CD97 activation.
Meng ZW; Zhang L; Cai XR; Wang X; She FF; Chen YL
Sci Rep; 2023 Oct; 13(1):18711. PubMed ID: 37907543
[TBL] [Abstract][Full Text] [Related]
14. Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.
Deng S; Zhang L; Li J; Jin Y; Wang J
Tissue Cell; 2022 Jun; 76():101756. PubMed ID: 35217388
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA NNT-AS1 promotes cholangiocarcinoma cells proliferation and epithelial-to-mesenchymal transition through down-regulating miR-203.
Gu Y; Zhu Z; Pei H; Xu D; Jiang Y; Zhang L; Xiao L
Aging (Albany NY); 2020 Feb; 12(3):2333-2346. PubMed ID: 32019904
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA MALAT1 promotes cholangiocarcinoma cell proliferation and invasion by activating PI3K/Akt pathway.
Wang C; Mao ZP; Wang L; Wu GH; Zhang FH; Wang DY; Shi JL
Neoplasma; 2017; 64(5):725-731. PubMed ID: 28592124
[TBL] [Abstract][Full Text] [Related]
17. Atractylodin and β-eudesmol from Atractylodes lancea (Thunb.) DC. Inhibit Cholangiocarcinoma Cell Proliferation by Downregulating the Notch Signaling Pathway.
Vanaroj P; Chaijaroenkul W; Na-Bangchang K
Asian Pac J Cancer Prev; 2023 Feb; 24(2):551-558. PubMed ID: 36853304
[TBL] [Abstract][Full Text] [Related]
18. The Proteomics and Metabolomics Analysis for Screening the Molecular Targets of Action of β-Eudesmol in Cholangiocarcinoma.
Kotawong K; Chajaroenkul W; Roytrakul S; Phaonakrop N; Na-Bangchang K
Asian Pac J Cancer Prev; 2021 Mar; 22(3):909-918. PubMed ID: 33773557
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of migration and invasion by berberine via inactivation of PI3K/Akt and p38 in human retinoblastoma cell line.
Wang Y; Yuan J; Yang L; Wang P; Wang X; Wu Y; Chen K; Ma R; Zhong Y; Guo X; Gong Y; Gui M; Jin Y
Adv Clin Exp Med; 2018 Jul; 27(7):899-905. PubMed ID: 29790698
[TBL] [Abstract][Full Text] [Related]
20. Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis.
Zhou QX; Jiang XM; Wang ZD; Li CL; Cui YF
Med Oncol; 2015 Apr; 32(4):105. PubMed ID: 25744243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
